| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 02/14/22 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
5 | |
| 02/04/22 | EFFECT | Notice of Effectiveness |
|
1 | |
| 02/02/22 | 8-K | Current report filing |
|
   |
12 |
| 02/01/22 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 02/01/22 | UPLOAD | SEC-generated letter |
|
1 | |
| 01/28/22 | S-3 | Registration statement for specified transactions by certain issuers |
|
31 | |
| 01/27/22 | 8-K | Current report filing |
|
|
13 |
| 01/14/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
64 |
| 01/04/22 | 8-K | Current report filing |
|
|
3 |
| 12/28/21 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
90 |
Lexaria Bioscience Corp.
Lexaria Bioscience Corp.